NDAINTRAVENOUSSOLUTION
Approved
Dec 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Topotecan hydrochloride is a small-molecule topoisomerase I inhibitor approved as an intravenous solution for treating select solid tumors. It works by inhibiting topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cancer cells. The drug targets patients with ovarian cancer, small cell lung cancer, and cervical cancer who have failed or are intolerant to first-line therapy.
Peak
Moderate competitive pressure (30%) suggests a mature market with established sales infrastructure and stable but not explosive growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Started Mar 2015
178 enrolled
Adult LiposarcomaMetastatic LiposarcomaMetastatic Osteosarcoma+4 more
Career Relevance
Working on topotecan offers stable, mature-market experience in oncology but limited growth trajectory; roles focus on maintaining market share against generics and newer competitors rather than launching or expanding. Best suited for professionals seeking solid oncology commercial expertise without the excitement of a novel mechanism or breakthrough designation.
Brand Manager
Worked on TOPOTECAN HYDROCHLORIDE at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.